AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02217566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Participants will receive abiraterone acetate 1000 mg (4\*250 mg tablets) orally once daily until PSA progression, clinical progression, consent withdrawal, or the occurrence of unacceptable toxicity.
Study NCT02217566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Participants will prednisone 5 mg orally once daily from Day 1 of Cycle 1 and continues until PSA progression, clinical progression, consent withdrawal, or the occurrence of unacceptable toxicity.
Study NCT02217566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Description: Participants will remain on a stable regimen of ADT, that is, luteinizing hormone-releasing hormone (LHRH) agonists including leuprolide acetate and goserelin acetate as per Investigator's discretion.
Study NCT03195478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT03195478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study NCT01077973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novel Ibuprofen
Description: Single-dose of novel ibuprofen (equal to 400 mg ibuprofen) plus placebo
Study NCT01077973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Ibuprofen
Description: Single-dose of standard ibuprofen (400mg) plus placebo
Study NCT01077973 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single-dose of placebo
Study NCT04762628 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MAF capsules 148 mg
Description: enteric capsules based on enzymatically treated bovine colostrum
Study NCT04762628 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: M capsules 148 mg
Description: enteric capsules based on enzymatically treated bovine whey
Study NCT04762628 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care
Study NCT00328146 — intervention group
Intervention type: OTHER
Intervention: Observation of sternal reentry
Description: Observation of sternal reentry
Study NCT04393610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Patients will receive lidocaine 3 mg/kg total of 40 ml (control group).
Study NCT04393610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulphate
Description: Patients will receive lidocaine 3 mg/kg total of 40 ml plus Magnesium sulphate 30 mg/kg maximum 1.5 gm, mixed with the second 20 ml of block solution.
Study NCT04393610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Patients will receive lidocaine 3 mg/kg total of 40 ml plus fentanyl 1 mcg/kg, mixed with lidocaine given after the first 20 ml of block solution.
Study NCT03362775 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Propofol
Description: Target-controlled infusion of propofol with an effect-site concentration of 0.0 µL/mL; 0.5 µL/mL and 1.0 µL/mL.
Study NCT01032551 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vascular Access Decision Aid
Description: The intervention group will receive a PtDA addressing vascular access for CA procedures. The PtDA is a brief lay summary that outlines, the purpose of the PtDA, a description of both femoral and radial approaches for CA procedures, what to expect from both approaches, the known risks/benefits of each access site (including a grading of the evidence), and a short assessment of the patients values. The values assessment is included in the PtDA as a means to help guide the patient through the decision making process. This section will ask the patient to explicitly state which features, risks, and benefits of each approach are important to them.
Study NCT03093038 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: H-MAX stem & Delta-TT cup + polyethylene
Description: H-MAX femoral stem \& Delta-TT cup with a polyethylene insert
Study NCT03093038 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: H-MAX stem & Delta-TT cup + ceramic
Description: H-MAX femoral stem \& Delta Delta-TT cup with a Ceramic insert
Study NCT03093038 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C2 stem & Delta-TT cup + ceramic
Description: C2 femoral stem Delta Delta-TT cup with a Ceramic insert
Study NCT01750515 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Study NCT00924937 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: Mediterranean Diet:35-38% fat (22% MUFA; 6% PUFA; \<10% SAT).
Study NCT00924937 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Fat Diet
Description: Low fat diet: \<30% fat (12% MUFA; 6-8%PUFA; \<10% SAT)
Study NCT00323557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim (GM-CSF)
Description: Starting with 3 doses of 250 micrograms subcutaneously, either pre or post vaccine. For pre vaccine, GM-CSF on days -7 (+ 1 day) and -3 (+ 1 day), in the week prior to vaccination for pre-vaccination immune priming; 3rd dose on the day of vaccination (day 0); and for post-vaccine GM-CSF given simultaneously on day of vaccination (day 0) and 2 more doses Day +3 and Day +7 after pneumococcal vaccine.
Study NCT00323557 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Vaccine
Description: Subcutaneously on Day 0
Study NCT00684957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Growth Hormone
Description: 300 mcg sc qd (which may be increased to 400 mcg sc qd after 4 weeks)
Study NCT00684957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human IGF-1
Description: 30 µg/kg for first 4 weeks (may be increased thereafter based on IGF-1 levels)
Study NCT00684515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorapaxar 2.5 mg
Description: Oral tablets; once daily for 60 days.
Study NCT00684515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorapaxar 1 mg
Description: Oral tablets; once daily for 60 days
Study NCT00684515 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablets; once daily for 60 days
Study NCT00684515 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin 75-150 mg
Description: oral tablets; once daily for 60 days
Study NCT00684515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 75-150 mg
Description: oral tablets; once daily for 60 days
Study NCT04389242 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: REST Online（Reduce Stress Tour Online）
Description: Different cognitive behavioral skills are introduced and practiced in a 8 weekly online program, which includes animation briefing and debriefing, case demonstration video, exercise, forum, internal messaging, online assessment and reminder. One face-to-face session and one telephone follow-up provided by an experienced CBT therapist are also provided to clients.
Study NCT04389242 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: REST Online（Reduce Stress Tour Online）
Description: Different cognitive behavioral skills are introduced and practiced in a 8 weekly online program, which includes animation briefing and debriefing, case demonstration video, exercise, forum, internal messaging, online assessment and reminder. One face-to-face session and one telephone follow-up provided by an experienced CBT therapist are also provided to clients.
Study NCT03244033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contextual clinical decision support
Description: Incorporation of contextual data into EHR clinical decision support alerts
Study NCT03244033 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contextual survey
Description: Patients complete a survey asking about red flags that could signal contextual factors relevant to their care
Study NCT03244033 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contextual survey
Description: Patients complete a survey asking about red flags that could signal contextual factors relevant to their care
Study NCT00859703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate
Description: 35mg oral risedronate once per week for 24 months
Study NCT00859703 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 35 mg once a week for 24 months
Study NCT04507984 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Genetic analysis
Description: After obtaining written consent from patients, DNA is isolated, and genetic analysis of the know familial hypercholesterolemia disease-causing genes (LDLR, APOB, PCSK9) is performed.
Study NCT04507984 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lipid levels measurement
Description: Measurements of lipid levels (total cholesterol, LDL-cholesterol, HDL-cholesterol, TG) using standard methods.
Study NCT00813397 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sepraspray
Description: Max. 10g of Sepraspray
Study NCT02272686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: 560 mg by mouth daily.
Study NCT01707615 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSPE
Description: GSPE 240 mg/day (120mg bid)
Study NCT01707615 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lifestyle intervention
Description: dietary modification making the total ingestion of calories into standard body weight 25 kCal in effect and an individualized home exercise program of a minimum 150 min/week of moderate-intensity physical activity
Study NCT01707615 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: lifestyle intervention
Description: dietary modification making the total ingestion of calories into standard body weight 25 kCal in effect and an individualized home exercise program of a minimum 150 min/week of moderate-intensity physical activity
Study NCT03085914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat oral twice-daily continuous daily dosing at the protocol-defined dose.
Study NCT03085914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab
Study NCT02011191 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Biotin Supplementation
Description: 10,000 micrograms biotin supplement daily for 8 weeks
Study NCT02011191 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: Identical sugar pill, identical bottle as the biotin supplementation group
Study NCT02305693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Study NCT02305693 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic ovarian drilling
Study NCT03222349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam Buccal Film
Description: Subjects received a single DBF dose determined by age and body weight during the interictal state and during the ictal/peri-ictal period with at least 14 days washout between doses.
Study NCT03555266 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NSS-2 Bridge
Description: NSS-2-Bridge auricular therapy will be given in addition to standard of care ERAS protocol.
Study NCT03555266 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham NSS-2 BRIDGE
Description: NSS-2-Bridge sham will be used in addition to standard of care ERAS protocol.
Study NCT01744288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Oral single loading dose 180ng
Study NCT01744288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Oral single loading dose 600mg
Study NCT01744288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA
Description: 81mg once daily from day -2 up to platelet transfusion
Study NCT01744288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASA
Description: 81mg once daily from day -2 up to platelet transfusion
Study NCT02582957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sigh breaths
Description: Sigh breaths delivered once every 6 minutes, as part of usual invasive mechanical ventilation.
Study NCT03675880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAB014
Description: TAB014 of 1.25mg(0.05ml)、2.00mg(0.08ml)、2.50mg(0.10ml)
Study NCT03704870 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Chest Xray
Description: Daily chest xray
Study NCT03704870 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: No daily chest xray
Description: Chest xray will be done post chest tube removal only
Study NCT03317769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Plasticity-Based Adaptive Cognitive Training
Description: Training on computerized exercises that targets social cognition for 2 hours per week.
Study NCT03317769 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available computerized training
Description: Training on computerized, casual video games for 2 hours per week.
Study NCT03317769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimized social skills training
Description: Group-video calls with Specialist for 1 hour per week where participants can interact with Specialist individually or as a group. Specialist will provide guidance, support and feedback, and send links and articles about information and topics discussed during the video calls.
Study NCT03317769 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unstructured support group sessions
Description: Unstructured support group-video calls for 1 hour per week. The Specialist will not engage with participants (eg. providing participants with links to articles and additional support) or provide guidance for the group discussion.
Study NCT01392820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Tablet, Oral, twice daily
Study NCT01392820 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, Oral, twice daily
Study NCT03369145 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-fat diet
Description: The high-fat diet will provide 7 days of overfeeding comprising of: +50% extra calories above the daily required intake, 65% of which is fat.
Study NCT01243736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination Prep
Description: combination bowel preparation, which consists of:~1. drinking 2-liters (8 cups) of polyethylene glycol starting at 7 p.m. the night prior to the capsule endoscopy test;~2. drinking a teaspoon of simethicone 20 minutes prior to the capsule endoscopy test;~3. drinking a teaspoon of metoclopramide 20 minutes prior to the capsule endoscopy test;~4. lying on your right side for 30 minutes following the swallowing of the capsule endoscope.
Study NCT01500356 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention
Description: Weight loss intervention that focuses on reducing energy intake.
Study NCT01500356 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet Plus Moderate Exercise
Description: Weight loss intervention that involve an energy restricted diet (identical to the Diet Alone arm) plus the inclusion of 150 minutes per week of moderate-intensity exercise.
Study NCT01500356 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet Plus High Exercise
Description: Weight loss intervention that involve an energy restricted diet (identical to the Diet Alone arm) plus the inclusion of 250-300 minutes per week of moderate-intensity exercise.
Study NCT04536883 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microscopy confocal
Description: At this stage, the confocal microscopy procedure begins:~Taking pictures for post-procedure analysis in 4 different territories. For each territory, the investigator need to get a snapshot of a vascular structure and a snapshot of an alveolus.~Analysis per procedure: the same operator analyzes the alveoli deemed to be representative in real time. It determines the presence of intra-alveolar inflammatory cells and answers the question of the main criterion: possible interpretation in confocal microscopy? YES / NO, the clinical researcher immediately notes the answer in the CRF. Based on this per-procedure analysis, if he deems the interpretation possible, the operator declares if he concludes that pulmonary inflammation is present YES / NO, the response is noted immediately in the CRF.~The fibroscopy procedure is then resumed as usual in the department, namely:
Study NCT03686566 — intervention group
Intervention type: DRUG
Intervention: 13C-glucose
Description: Includes standard pre-operation nursing care, 13C-glucose infusion and finger stick/IV glucose checks and storage of blood sample approximately every 30 minutes
Study NCT03686566 — intervention group
Intervention type: OTHER
Intervention: No glucose infusion
Description: Only includes standard pre-operation nursing care
Study NCT00699907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: flutamide
Description: Patients receive oral flutamide (125 MG/DAY) once daily for 6 weeks in the absence of unacceptable toxicity.
Study NCT03796767 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated radiation therapy
Study NCT03796767 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study NCT03796767 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metastasectomy
Description: Undergo salvage oligometastasectomy
Study NCT03796767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03796767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03796767 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT03085914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin
Study NCT00703664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib: 1.3 mg/m\^2/d IV days 1, 4, 8, and 11.
Study NCT00703664 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00703664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat: 400 mg (total daily dose as a single dose) days 1-5 and 8-12.
Study NCT03085914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin
Study NCT03572556 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: * 5 mL dry tube to separate serum~* Two 6 mL EDTA tubes for plasma separation~* Eight 6 mL heparinized tubes for flow cytometry (quantification of TANG such as CD3+CD31+CXCR4+ and CEC) and quantification of angiogenesis markers.
Study NCT03572556 — intervention group
Intervention type: OTHER
Intervention: Epistaxis charts
Description: Three monthly epistaxis charts to be completed
Study NCT04302532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Description: antioxidant used to decrease oxidative stress and improve fertility prospects
Study NCT04302532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clomiphene citrate
Description: ovulation induction drug
Study NCT04302532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clomiphene citrate
Description: ovulation induction drug
Study NCT00868686 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Volar aluminum splint
Description: Alumafoam strip with padding removed, placed on the VOLAR aspect of the digit spanning the middle and distal phalanges only.
Study NCT00868686 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dorsal aluminum splint
Description: Alumafoam strip with padding removed, placed on the DORSAL aspect of the digit spanning the middle and distal phalanges only.
Study NCT00868686 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Custom thermoplastic
Description: Customized thermoplastic splint with circumferential contact proximal to the joint and volar contact distal to the joint. This is a similar design to the original Stack splint, except that it is custom molded.
Study NCT01181414 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atrio ventricular junction ablation with radio-frequency
Description: Atrioventricular junction ablation by using radiofrequency energy.
Study NCT01181414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta blocker/digoxine/amiodarone
Description: Ventricular rate control by using drug treatment.
Study NCT04663178 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warm Salt Water Foot Bath
Description: A training booklet about chemotherapy-induced fatigue + 20-minute warm salt water application to their feet for a week after the treatment by explaining and showing the video prepared about the preparation and practice of warm salt water foot bath.
Study NCT00523991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium
Description: Oral inhalation once daily of 18mcg tiotropium via handihaler